Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Henning Olbrich, Christian D. Sadik, Ralf J. Ludwig, et al.
Biomolecules (2023) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Just scratching the surface: A review of pediatric skin allergies
Mary Grace Baker, Lara S. Ford, Dianne E. Campbell, et al.
Pediatric Allergy and Immunology (2025) Vol. 36, Iss. 2
Closed Access
A case of systemic contact dermatitis associated with a peritoneal dialysis catheter and treated with dupilumab
Kosuke Mochizuki, Jun Takeoka, Naohiro Toda, et al.
CEN Case Reports (2025)
Closed Access
Chronic Hand Eczema (CHE): A Narrative Review
G. Ghezzi, Costanza Falcidia, Giovanni Paolino, et al.
Dermatology and Therapy (2025)
Open Access
Update on the Treatment of Chronic Spontaneous Urticaria
Pavel Kolkhir, Jie Shen Fok, Emek Kocatürk, et al.
Drugs (2025)
Open Access
Discovery of a new anti-γc antibody in clinical development for the treatment of autoimmune diseases
Chin Wai Hui, Wai Chung Wu, Tak Keung Tong, et al.
The Journal of Immunology (2025)
Closed Access
Recalcitrant Nummular Eczema in Childhood Responsive to Dupilumab Treatment
Luisa R Romiti, Ana Flavia Moraes, Julia‐Tatjana Maul, et al.
Cureus (2025)
Open Access
Dupilumab for chronic actinic dermatitis: A case series and review of the literature
Zachary Holmes, Peter Foley, Christopher M. Baker, et al.
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 3, pp. 287-291
Closed Access | Times Cited: 3
Refractory Hailey–Hailey disease cleared with upadacitinib
Lauren Murphy, Peter Ch’en, Eingun James Song
JAAD Case Reports (2023) Vol. 41, pp. 64-67
Open Access | Times Cited: 7
Dupilumab improves itch and blistering in different subtypes of epidermolysis bullosa
Stella Gewert, Miodrag Davidovic, Cristina Has, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 8, pp. 1139-1144
Open Access | Times Cited: 2
Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children
Huijuan Fang, Fengchuan Zhang, Wenjun Lin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases
Katarzyna Antosz, Joanna Batko, Marta Błażejewska, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1531-1531
Open Access | Times Cited: 2
New Perspectives in the Management of Chronic Hand Eczema: Lessons from Pathogenesis
Vittorio Tancredi, Dario Buononato, Stefano Caccavale, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 362-362
Open Access | Times Cited: 6
Dupilumab: Two sides of a side‐effect
Peter H. Hoeger
Pediatric Dermatology (2024) Vol. 41, Iss. 1, pp. 180-181
Closed Access | Times Cited: 1
Dupilumab verbessert Juckreiz und Blasenbildung bei verschiedenen Subtypen der Epidermolysis bullosa
Stella Gewert, Miodrag Davidovic, Cristina Has, et al.
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 8, pp. 1139-1144
Open Access | Times Cited: 1
Role of interleukins in dermatology: Exploring the immune mechanisms in skin diseases
Álvaro Prados‐Carmona, F.J. Navarro‐Triviño, Ricardo Ruíz‐Villaverde, et al.
JEADV Clinical Practice (2024)
Open Access | Times Cited: 1
Atopic dermatitis: pathogenesis and therapeutic intervention
Chengcheng Yue, Hong Zhou, Xiaoyan Wang, et al.
MedComm (2024) Vol. 5, Iss. 12
Closed Access | Times Cited: 1
A critical review of dupilumab for adult patients with prurigo nodularis
Georgia Biazus Soares, Gil Yosipovitch
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 3, pp. 249-254
Closed Access | Times Cited: 3
Autoimmune blistering diseases: promising agents in clinical trials
Henning Olbrich, Christian D. Sadik, Enno Schmidt
Expert Opinion on Investigational Drugs (2023) Vol. 32, Iss. 7, pp. 615-623
Closed Access | Times Cited: 2
Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita
Natalie Groß, Jana Marketon, Sadegh Mousavi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Advancements in Ichthyosis Treatment in Pediatric Patients: Evaluating the Impact of Immune System Inhibitors Targeting TNF-alpha, IL-17A, IL-4, and IL-12
Eiman Hamza Ahmed Elsayed, Rabab Elsayed Ali Hassan Khater
American Journal of Life Science and Innovation (2024) Vol. 3, Iss. 1, pp. 69-74
Open Access
Treatment of COPD with a particular focus on biological therapy: a systematic review
Kinga Ziojła-Lisowska, Agnieszka Kuzio, Aleksandra Cieplińska
Quality in Sport (2024) Vol. 17, pp. 53022-53022
Open Access
Treatment of Epidermolysis bullosa acquisita with dupilumab
R. Diehl, Dimitra Kiritsi, Franziska Schauer
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 10, pp. 1417-1419
Open Access
A comprehensive analysis on the safety of two biologics dupilumab and omalizumab
Yu Xiao, W.H. Yang, M M Wang
Frontiers in Medicine (2024) Vol. 11
Open Access
Use of dupilumab for recalcitrant bullous pemphigoid: A case report
Jillian Lamb, Kerri Purdy, Ashley Sutherland
SAGE Open Medical Case Reports (2024) Vol. 12
Open Access
Continued contribution to atopic innovation with dupilumab
Alex E Wright, W. C. Wood, Aakash Goyal
Current Opinion in Pediatrics (2024) Vol. 36, Iss. 5, pp. 537-541
Closed Access
Page 1 - Next Page

Scroll to top